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Treg Th2 Respiratory exposure to innocuous antigens generally results in immunologic tolerance. 1 On the other hand, patients with allergic airway diseases show chronic and persistent inflammatory responses to environmental antigens 2 that are mediated by T H 2-type CD4 1 T cells. 3, 4 A novel subset of memory CD4 1 cells that produces both T H 2-type cytokines and IL-17 has also been identified in patients with severe asthma. 5 Thus a fundamental question remains as to why airway tolerance is compromised in patients with allergic airway diseases. Regulatory T (Treg) cells that develop in the peripheral mucosal tissues protect against T H 2-type inflammation in the gastrointestinal tract and lungs. 6 Indeed, impaired development of antigen-specific forkhead box P3 (Foxp3) 1 Treg cells is implicated in loss of immunologic tolerance to inhaled allergens. 7, 8 Other studies also suggest that Treg cells are involved in controlling the development and resolution of allergic diseases. [9] [10] [11] [12] [13] Accordingly, the balance between the activation of T H 2-type immunity and the regulatory activity of Treg cells might play a pivotal role in the evolution of allergic airway diseases.
IL-33, which is produced by the airway epithelium and other cell types, is likely to be critical in mediating type 2 immune responses in patients with asthma. [14] [15] [16] [17] Genome-wide association studies of patients with asthma have shown that polymorphisms in IL33 and IL1RL1 (ie, the IL-33 receptor ST2) are associated with an increased susceptibility to asthma. [18] [19] [20] [21] 22 In the murine model of asthma, IL-33 induces T H 2-type differentiation of naive CD4 1 T cells and promotes production of IL-5 and IL-13, hence amplifying airway hyperresponsiveness and eosinophilic airway inflammation. 16 When added to resting T H 2 cells together with signal transducer and activator of transcription 5-activating cytokines, IL-33 enhances their expression of ST2. 17 IL-33 also mediates development of highly pathogenic T H 2-type T cells that produce a large quantity of IL-5. 23 However, little information is currently available regarding the effects of IL-33 on Treg cells.
Although the immunosuppressive function of Treg cells has been well established, recent studies have recognized that Treg cells are plastic and demonstrate tissue-specific alteration. 24, 25 For example, Treg cells that express the canonical transcription factor Foxp3 have the propensity to coexpress retinoic acid receptor-related orphan receptor gt and differentiate into T H 17-type cells in the inflamed intestine. [26] [27] [28] Similarly, Foxp3 1 Treg cells that are recruited to a site of T H 1-type inflammation express T-box transcription factor and produce IFN-g. 29 More recently, T H 2 cell-like Treg cells have been identified in the intestines and secondary lymphoid organs in a mouse model of food allergy involving a gain-of-function IL-4 receptor a chain allele. 9 In human subjects Treg cells that express type 2 cytokines, such as IL-4 and IL-13, were detected in the skin of patients with systemic sclerosis. 30 Thus Treg cells are likely altered when influenced by certain tissue microenvironments. However, our knowledge about Treg cell plasticity in patients with allergic airway diseases and their models and regulation of that plasticity is limited. Accordingly, to fill these major gaps in our knowledge, we investigated the roles of IL-33 in controlling Treg cells. Our observations suggest that IL-33 alters lung Treg cells and impairs airway tolerance to airborne allergens. Hence in addition to its established effects on T H 2-type effector T cells and ILC2s, IL-33 might promote type 2 airway inflammation by modulating mucosal Treg cells.
METHODS
See the Methods section in this article's Online Repository at www. jacionline.org for more details. 
Gene expression analyses
Cells were lysed in Trizol (Invitrogen, Carlsbad, Calif), and total RNA was extracted and purified by using the PureLink RNA Mini Kit (Thermo Fisher Scientific, Waltham, Mass), followed by real-time quantitative RT-PCR (qRT-PCR) analyses. The relative expression level was determined by using the 2 2DDCT method. 31 CD4 cells were isolated from spleens of naive BALB/c Foxp3 EGFP reporter mice by means of sorting, as described above. T-responder cells were labeled with Violet Cell Tracer dye (Thermo Fisher Scientific). T-responder cells were incubated in 48-well plates at 1 3 10 6 cells/mL in the presence of anti-CD3/anti-CD28 Dynabeads (20 mL of microbeads in 1.0 mL, Thermo Fisher Scientific) with or without Treg cells at a ratio of 1:1. IL-33 at 40 ng/mL was added to some cultures. After a 4-day incubation, the proliferation of T-responder cells was analyzed by using flow cytometry.
Airway tolerance model
Endotoxin-free ovalbumin (OVA) was prepared, as previously described. 32 Airway immunologic tolerance to OVA was induced by using a similar protocol, as previously described. 7, 33 Briefly, endotoxin-free OVA (100 mg per dose) was intranasally administrated to naive BALB/c mice from day 212 to day 27. OVA (10 mg per dose; Sigma-Aldrich, St Louis, Mo) plus alum was injected intraperitoneally on days 7 and 14 to verify the state of immunologic tolerance. Control mice received sterile PBS plus alum. Peripheral blood was collected on day 28 to examine plasma levels of IgE antibodies to OVA. On days 29, 30, and 31, mice were challenged intranasally with endotoxin-free OVA (100 mg per dose). On day 32, bronchoalveolar lavage (BAL) fluid and lung tissue were collected for analyses.
Allergen-induced airway inflammation model
Mice were exposed to extracts of natural allergens, as described previously, to examine the effects of exposure to natural allergens. 32 
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2 conventional T cells in both spleens and lungs of naive mice (Fig 1, A) . In contrast, a fraction of CD4 (Fig 1, B) ; some expression of ST2 was observed in conventional CD4
1 T cells (ie, Foxp3 2 cells) in the lungs as well. Quantitative analyses showed that proportions of ST2 1 cells in both Treg cell and conventional CD4
1 T-cell populations were significantly higher in the lungs compared with those in the spleen (P < .01; Fig 1, C) .
We verified this observation by examining mRNA expression. Previous studies also showed that IL-33 together with signal transducer and activator of transcription 5-activating cytokines enhances the expression of ST2 in resting T H 2 cells. 17 (Fig 2, A) . In colons of naive mice, GATA3 is expressed by an ST2 1 population of Treg cells. 35 In the lungs small but apparent expression of GATA3 protein was detectable in CD4 1
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1 Treg cells from naive mice and mice treated with PBS (Fig 2, B) . Administration of IL-33 significantly increased the total number of lung When we analyzed mRNA expression in isolated cells, no differences were observed in expression levels of Gata3 and Foxp3 mRNA in CD4
1
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1 Treg cells from PBS-and IL-33-exposed mice (Fig 2, D) . In contrast, Il5 and Il13 mRNA were highly expressed by 100-to 1000-fold in Treg cells from IL-33-exposed animals compared with naive or PBS-treated animals. When isolated CD4
1 Foxp3eGFP 1 Treg cells were further stimulated with PMA plus ionomycin in vitro, significant amounts of IL-5 and IL-13 proteins, but not IL-4, IL-17, or IFN-g proteins, were detected in the cell-free supernatants of Treg cells from IL-33-exposed mice (P < .01; Fig 2, E) . None of these cytokines were detectable in Treg cells from PBS-exposed mice. In contrast, the level of active TGF-b appeared to decrease in IL-33-exposed mice compared with that in PBS-exposed mice (P 5 .06).
Lung single-cell suspensions from Foxp3 EGFP reporter mice that had been exposed to IL-33 were restimulated with PMA and ionomycin in vitro for 6 hours in the presence of GolgiPlug (BD Biosciences, San Jose, Calif) to elucidate the source of IL-5 and IL-13 within lung Treg cell populations. Cells were stained for Foxp3 and GATA3, intracellular IL-5 and IL-13, and cell-surface CD4 and ST2 and analyzed by using flow cytometry. No or minimal expression of ST2, IL-5, or IL-13 was observed in the GATA3 2 population of Foxp3 1 Treg cells (Fig 2, F) . In contrast, the GATA3 
2 ) from spleens of naive Foxp3 EGFP mice by means of sorting. Although we recognize that this experiment should ideally be performed with lung T cells, the poor yield of lung Treg cells from naive mice did not allow us to perform an in vitro culture experiment. T-responder cells were labeled with a cell tracer dye to monitor proliferation, and they were stimulated with anti-CD3 and anti-CD28 microbeads. This strategy was used to rule out the potential effects of IL-33 on antigen-presenting cells (APCs), such as dendritic cells (DCs), that might have occurred if we had used an antigen and APCs. When stimulated with anti-CD3/anti-CD28 without Treg cells, T-responder cells proliferated (Fig 3, A and B) ; the responder cell proliferation was not affected by IL-33. When Treg cells were added, proliferation of T-responder cells was markedly reduced. Nonetheless, in the presence of IL-33, proliferation of T-responder cells was restored, even in the presence of Treg cells. Quantitative analyses showed that the percentage of nonproliferated T-responder cells significantly increased in the presence of Treg cells and the number decreased to the level that is comparable with that without Treg cells in the presence of IL-33 (P < .01; Fig 3, C) . These results suggest IL-33 impaired the suppressive ability of Foxp3 1 Treg cells in vitro, whereas IL-33 showed minimal effects on proliferation of naive T-responder cells.
Culture with IL-33 induces T H 2 cell-like Treg cells in vitro
The above observations led us to speculate that lung Treg cells might respond directly to IL-33, resulting in a T H 2 cell-like EGFP reporter mice by means of sorting and cultured them in vitro with IL-33 for 96 hours. IL-2 was added to all the cultures to maintain cell viability, but no agonists for T-cell receptor were included. No apparent differences were observed in expression levels of Gata3 and Foxp3 mRNA in Treg cells cultured with or without IL-33 (Fig 4, A) . In contrast, Il5 and Il13 mRNA was highly expressed in Treg cells cultured with IL-33. When the cells were further stimulated with PMA plus ionomycin, significantly greater amounts of IL-5 and IL-13 proteins, but not IL-4, IL-17, or IFN-g proteins, were detected in the cell-free supernatants of Treg cells that had been cultured with IL-33 (P < .01; Fig 4, B) .
IL-33 broke down established airway tolerance in vivo
Because IL-33 altered lung Treg cells, causing them to become T H 2 cell-like cells both in vitro and in vivo, and impaired their suppressive function, we hypothesized that IL-33 might impair established airway immunologic tolerance that is known to be mediated by Treg cells. 7, 8 To test this hypothesis, we used an established mouse model of airway tolerance in which mice are exposed to an innocuous antigen through the airways before sensitization. 7, 33 We exposed naive BALB/c mice to OVA intranasally for 5 consecutive days; the state of airway tolerance was verified by attempting to sensitize these mice by means of intraperitoneal injection of OVA plus alum and challenging them by means of intranasal administration of OVA 3 weeks later (see Fig E2, A, in this article's Online Repository at www.jacionline. org). When mice were previously exposed intranasally to PBS (as a control of tolerance induction), they were sensitized by intraperitoneal injection of OVA plus alum, resulting in increased serum levels of OVA-specific IgE and IgG 1 antibodies (see Fig E2, B) . These mice had marked airway eosinophilia and increased BAL levels of IL-5 and IL-13 when they were challenged with intranasal administration of OVA (see Fig E2,  C) . In contrast, when mice were previously exposed intranasally to OVA to induce tolerance, the development of OVA-specific IgE and IgG 1 in plasma and type 2 immune responses in the airways were severely impaired, which is consistent with previous observations. 7, 33 To investigate the effects of IL-33 on established airway immunologic tolerance, we administered OVA with or without IL-33 intranasally to mice that had been previously tolerized to OVA (Fig 5, A) . As described above, without airway tolerance induction (intranasal administration of PBS), mice sensitized by means of intraperitoneal injection of OVA plus alum showed increased plasma levels of anti-OVA IgE, marked eosinophilic airway inflammation, and increased BAL fluid levels of IL-5 and IL-13 when they were subsequently challenged with intranasal OVA (Fig 5, B and C) . In contrast, when mice were tolerized by means of prior intranasal administration of OVA, intraperitoneal injection of OVA plus alum did not sensitize those mice, and all the immune responses, as described above, were significantly reduced or abolished (P < .05 or P < .01). Nonetheless, when these previously tolerized mice were exposed to OVA with IL-33 intranasally, they had anti-OVA IgE antibody in plasma; OVA alone showed minimal effects. When these mice were subsequently challenged by means of intranasal administration of OVA, they had robust airway eosinophilia and increased BAL fluid levels of IL-5 and IL-13 that were higher than those achieved by means of intraperitoneal sensitization with OVA plus alum in nontolerized mice.
Because IL-33 can activate ILC2s and mast cells, [39] [40] [41] we questioned whether IL-33 alone without antigen is sufficient to break airway immunological tolerance. However, when mice were given IL-33 alone intranasally, the tolerized mice did not have anti-OVA IgE, airway eosinophilia, or type 2 immune responses (see Fig E3 in this article' s Online Repository at www.jacionline.org), suggesting that both antigen and IL-33 are concomitantly necessary to impair established tolerance.
Histologic analyses showed that nontolerized mice that were subsequently sensitized by means of intraperitoneal OVA plus alum had peribronchial infiltration of inflammatory cells and mucosal hyperplasia when challenged with intranasal OVA (group B; see Fig E4 in this article's Online Repository at www.jacionline.org). The tolerized mice that were subsequently sensitized by means of intraperitoneal OVA plus alum (group C) had minimal pathologic changes. In contrast, the tolerized mice that were subsequently exposed to OVA plus IL-33 intranasally (group D) had comparable airway pathologic changes similar to those of nontolerized mice.
A potential caveat of the design of the experiment, as described above, is that we verified the state of tolerance by means of intraperitoneal injection of OVA plus alum; this process might favor break down of tolerance when mice are subsequently exposed to OVA with IL-33 intranasally. To examine this possibility, we tolerized mice by means of intranasal administration of OVA, and then those mice were subsequently exposed to OVA with intranasal IL-33 without prior intraperitoneal administration of OVA plus alum (Fig 6, A) . As described above, the OVA-tolerized mice that were subsequently sensitized by means of intraperitoneal injection of OVA plus alum showed minimal plasma levels of IgE antibody and type 2 inflammation in the airways (Fig 6, B and C) . When tolerized mice were subsequently exposed to OVA plus IL-33 intranasally and then challenged with OVA intranasally, they had significant airway inflammation, consisting of neutrophils and eosinophils, as well as marked increase in BAL fluid levels of IL-5 and 
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1 cells isolated from naive nontreated Foxp3 EGFP mice. B, Cells were stimulated with PMA plus ionomycin for 6 hours. Cytokine levels in cell-free supernatants were analyzed by means of ELISA. Data (n 5 6, means 6 SEMs) are a pool of 2 independent experiments. *P < .05 and **P < .01 compared with IL-2 alone. Fig 6, C) . Interestingly, a minimal increase in IgE antibody levels was observed in these mice (Fig 6, B) . Altogether, these findings suggest that inhalation of antigen together with IL-33 was sufficient to convert previously established airway tolerance to T H 2-type immune responses in the airways.
IL-13 (
Lung Treg cells demonstrated T H 2 cell-like characteristics during allergen-induced airway inflammation
The experiments thus far described used exogenous IL-33 to drive T H 2-type airway immune responses. A major feature of patients with asthma is chronic and persistent airway inflammation, [42] [43] [44] which is likely mediated by exposure to environmental allergens, microbes, or other factors. Therefore, to elucidate whether dysregulated T H 2 cell-like Treg cells, as described above, develop in more physiologic models, we exposed mice to a mixture of natural airborne allergen extracts, including Alternaria alternata, A fumigatus, and HDM, together with OVA, as described previously (Fig 7, A) 
33
; marked type 2 airway inflammation in this model was dependent on IL-33 and thymic stromal lymphopoietin. 32 A 2-week exposure of naive BALB/c Foxp3 EGFP mice to these allergen extracts induced airway inflammation, which was characterized by increased numbers of eosinophils and other inflammatory cells in BAL fluid (Fig 7, B) . FACS analyses of CD4
1 T cells in the lungs showed that a proportion (approximately 30%) of Foxp3eGFP 1 Treg cells expressed ST2 (Fig 7, C and D) . The total number of Treg cells also increased significantly compared with numbers in mice exposed to PBS (P < .01). To characterize these ST2
1 Treg cells, we sorted them and analyzed them using real-time qRT-PCR. ST2
1 Treg cells from mice exposed to allergens showed a significant increase in Il5 and Il13 mRNA expression compared with those from PBS-exposed mice (P < .05 and P < .01; Fig 7,  E) . However, no differences were observed in expression of Gata3 and Foxp3 mRNA. These findings suggest that, similar to the results in IL-33-exposed mice (Fig 2) , numbers of T H 2 cell-like Treg cells increased in the lungs during allergeninduced airway inflammation.
To examine the roles of IL-33 in the development of these T H 2 cell-like Treg cells in the allergen exposure model, we used St2 2/2 mice. We exposed naive WT BALB/c or St2 2/2 mice to allergens and analyzed GATA3 protein expression to identify T H 2 cell-like Treg cells (Fig 8, A) because ST2 cannot be used as a marker in St2 2/2 mice. In WT mice exposed to PBS, approximately 2% of Foxp3 1 Treg cells were GATA3 1 (Fig 8,  B) . When exposed to allergens, the total number of Foxp3 
Treg cells and the proportion of GATA3
1 cells among the Treg cell population increased significantly (P < .05; Fig 8, B and C) . Approximately 10-fold higher numbers of GATA3
1 Treg cells were observed in mice exposed to allergens compared with those exposed to PBS. Furthermore, the development of GATA3 SEMs of 3 to 8 mice per group. *P < .05 and **P < .01 between the groups indicated by horizontal lines. Eos, Eosinophils; i.n., intranasal; i.p., intraperitoneal; Lym, lymphocytes; Mac, macrophages; Neu, neutrophils.
cells was nearly eliminated in ST2
2/2 mice (P < .01), suggesting that development of T H 2 cell-like Treg cells was largely dependent on the IL-33 pathway.
Finally, we verified the capacity of natural allergens to break established airway tolerance. By using a model analogous to that in Fig 6, we tolerized mice by means of intranasal administration of OVA, and those mice were subsequently exposed to OVA together with a mixture of allergen extracts (see Fig E5, A, in this article's Online Repository at www.jacionline.org). The OVA-tolerized mice that were subsequently sensitized by means of intraperitoneal injection of OVA plus alum showed minimal plasma levels of IgE antibody and type 2 inflammation in the airways (see Fig E5, B and C) . However, when tolerized mice were subsequently exposed to OVA plus a mixture of allergen extracts intranasally, they had a robust anti-OVA IgE antibody response. When challenged intranasally with OVA, they had significant eosinophilic airway inflammation and a significant increase in BAL levels of IL-5 and IL-13.
DISCUSSION
Previous studies show that lung-resident macrophages induce Foxp3
1 Treg cells in the lungs by producing TGF-b and retinoic acid, which promotes airway immunologic tolerance to environmental antigens. 8 Exposure to protease activities in allergens or infection with rhinovirus impairs development of these Treg cells by promoting expression of OX40 ligand by DCs and creating a lung environment rich in proinflammatory mediators, such as thymic stromal lymphopoietin, IL-33, IL-1, IL-6, and TNF-a. 7, 8, 45 These findings suggest the importance of the balance between TGF-b and proinflammatory cytokines/ molecules in the development of Treg cells in the lungs. Our findings in this study add to this knowledge by demonstrating that previously established Treg cells and immunologic tolerance in the lungs were not sustained in the presence of the innate cytokine IL-33. Numbers of dysregulated Treg cells that share characteristics of T H 2 cells also increased in the lungs of mice with allergen-driven IL-33-dependent airway inflammation.
We found that isolated lung Treg cells can be activated directly by IL-33 and enhance their expression of IL-33 receptor ST2 and type 2 cytokines, suggesting self-perpetuating effects of IL-33 on lung Treg cells (Figs 1 and 4) . Furthermore, airway exposure to IL-33 without antigens increased numbers of Foxp3 1 Treg cells, in particular those coexpressing the canonical T H 2 transcription factor GATA3 (Fig 2) . Although no changes in Gata3 mRNA expression levels were observed, GATA3 can be regulated by posttranscriptional mechanisms, such as phosphorylation of p38 46 or extracellular signal-regulated kinase, 47 and ubiquitination. 47 Furthermore, levels of GATA3 protein are regulated directly by mRNA stability and magnitude of translation. 48, 49 Therefore IL-33 might increase the levels of GATA3 protein, activate GATA3, or both, resulting in enhanced transcription of type 2 cytokine genes. A, Experimental protocol. Naive BALB/c Foxp3 EGFP reporter mice were exposed to PBS or a cocktail of airborne allergens, including extracts of A alternata, A fumigatus, and HDM and OVA, every other day for 2 weeks. BAL fluid and lung tissue were collected 12 hours after the last exposure. B, Cell differential counts in BAL fluid are shown. C, Single-cell suspensions of lungs were stained for CD4 and ST2 and analyzed by using FACS. Representative was isolated by means of sorting, and mRNA expression was analyzed by using real-time qRT-PCR. Data were normalized to levels of total Foxp3eGFP 1 Treg cells from naive mice. In Fig 7, B, D , and E, data are shown as means 6 SEMs of at least 3 mice per group and are representative of 2 independent experiments. *P < .05 and **P <.01 between the groups indicated by horizontal lines. Eos, Eosinophils; i.n., intranasal; Lym, lymphocytes; Mac, macrophages; Neu, neutrophils.
major role in expression of ST2 by Treg cells and their subsequent recruitment, expansion, or both in nonlymphoid organs. Our findings of lung Treg cells in mice that were exposed to exogenous IL-33 (Fig 2) or to natural airborne allergens (Fig 8) are consistent with these previous observations. The biological functions of these IL-33-responsive tissue Treg cells are an active area of investigation. For example, IL-33 promotes repair of chemically injured skeletal muscle injury, and the process appears to be mediated by a Treg cell subset producing amphiregulin. 50, 52 Similarly, in the lungs of mice infected with the influenza virus, amphiregulin derived from ST2
1 IL-33-responsive Treg cells limits lung pathology and improves oxygen exchange. 53 Treg cells also inhibit colonic inflammation in an IL-33-dependent manner through as yet unknown mechanisms. 35 Although detailed information as to whether IL-33-responsive Treg cells produce type 2 cytokines has not been available from these prior studies, we found that GATA3
1
ST2
1 Treg cells expressed Il5 and Il13 mRNA and produced IL-5 and IL-13 proteins when mice were exposed to IL-33 through the airways (Fig 2) . Comparable IL-5/IL-13-competent Treg cells were detected in the lungs of mice exposed to natural airborne allergens (Figs 7  and 8 ). GATA3 has been shown to be involved in upregulation of a unique set of genes, including Il5, Il13, Il1rl1 (ie, ST2), and Areg (ie, amphiregulin) in both ILC2s and T H 2-type CD4 
1 Treg cells might not be totally unpredictable.
T H 2 cell-like Treg cells have been reported recently in mice and human subjects. In a mouse model of food allergy involving a gain-of-function IL-4 receptor a chain allele, oral administration of an antigen and Staphylococcus enterotoxin B induces Treg cells that produce IL-4 9 ; mast cell-derived IL-4 contributes to the development of such T H 2 cell-like Treg cells. Treg cells that produce IL-5 and IL-13 were also identified in the skin of patients with systemic sclerosis. 9, 30 Thus Treg cells might be more plastic than previously predicted, 25 and their functions and phenotypes can be altered depending on their microenvironment. This could explain the apparent paradox in previous clinical studies. Indeed, large numbers of Treg cells are found at sites of ongoing inflammation. [55] [56] [57] [58] [59] [60] However, in the setting of chronic inflammation, whether these Treg cells are able to carry out their suppressive function, whether they are overwhelmed by increased numbers of effector T cells, or even whether they contribute to inflammation remained unclear.
In this study in the lung tissues of mice exposed to IL-33 or natural airborne allergens, the total number of Treg cells increased (Figs 2 and 7) . Nonetheless, these Treg cells, in particular those that coexpressed ST2 and GATA3, produced IL-5 and IL-13, suggesting that they might contribute to inflammation. Furthermore, in the presence of IL-33, Treg cells lost their ability to suppress the proliferation of effector T cells and were altered to produce type 2 cytokines (Figs 3 and 4) . In the intestinal mucosa Treg cells showed a propensity to express retinoic acid receptorrelated orphan receptor gt and differentiate into T H 17-type cells in patients with inflammatory conditions. 26, 27 Our study suggests that similar alterations in the functions and phenotypes of Treg cells can occur in the airway mucosa during type 2 airway inflammation. Further research is needed to examine which environmental cues help sustain suppressive function in Treg cells or, alternatively, drive them to acquire new functions, such as the production of type 2 cytokines. In addition, future clinical studies are necessary to address not only the quantities of Treg cells but also their functions.
Another major finding in this article is that the mice that had been previously tolerized to OVA and were unable to be sensitized by means of systemic administration of the antigen plus an adjuvant alum were sensitized to the same antigen when it was administered into the airways with IL-33 ( Figs 5 and 6 ). These observations suggest a potent adjuvant-like activity of IL-33 that not only induces type 2 immune responses in naive mice 16 but also breaks down established airway immunologic tolerance. Although isolated Treg cells can be activated directly by IL-33 (Fig 1) , we were unable to address directly whether such potent immunostimulatory activity of IL-33 is mediated by its actions on Treg cells, effector T cells, or both. It is also possible that IL-33 activates APCs, such as DCs, 61, 62 (eg, St2 fl/fl mice) will be necessary to address this remaining question once these mice become more widely available.
Nonetheless, our observations suggest instability of established airway immunologic tolerance that can be broken down by potent proinflammatory cytokines, such as IL-33. Recent clinical studies indicate several immunologic and biomedical pathways that define asthma phenotypes 63 ; onset of allergic or T H 2-type asthma can occur in childhood or the adult years. Our study provides an answer to why established immunologic tolerance or once well-controlled immunity in the lungs can become compromised later in life in some patients. In addition, IL-33 can contribute to the immunopathology of persistent asthma by activating ILC2s and airway epithelial cells. 64 Thus further studies to elucidate the immunologic mechanisms of IL-33 production and its biological effects on immune cells and immune systems can provide a better understanding of the pathogenesis of certain airway diseases and development of new prevention and treatment strategies for them. 
METHODS FACS analyses of lung and splenic Treg cells
Lungs were harvested from naive Foxp3 EGFP reporter mice or Foxp3 EGFP St2 2/2 reporter mice that were killed with an overdose of pentobarbital. Alternatively, Foxp3 EGFP mice were exposed intranasally to PBS or IL-33 (100 ng per dose, eBioscience) on days 0, 2, and 4. Twelve to 24 hours after the last exposure, mice were killed, and lungs were collected. Minced spleen or lung tissue was incubated with 0.08 W€ unsch units/mL of Liberase (Roche) and 26 mg/mL DNase I (STEMCELL Technologies) in RPMI 1640 medium (Gibco, Rockville, Md) for 1 hour at 378C. Red blood cells were lysed with ammonium chloride/potassium lysing buffer, and single cells were washed and resuspended in PBS containing 1% BSA. In some experiments lung single-cell suspensions were cultured in 24-well plates at 5 3 10 6 cells/mL and stimulated for 6 hours with 10 ng/mL PMA plus 500 ng/mL ionomycin in the presence of GolgiPlug in RPMI 1640 medium with 10% FBS (Hyclone, Logan, Utah), 50 mmol/L 2-mercaptoethanol, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (complete medium).
For staining, cells were preincubated with Fc receptor blockers for 30 minutes at 48C and stained with combinations of peridinin-chlorophyllprotein complex-Cy5.5-conjugated anti-CD4 (clone RM4-5, BD Biosciences) or Brilliant Violet 785-conjugated anti-CD4 (clone RM4-5; BioLegend, San Diego, Calif) and biotin-conjugated anti-ST2 (DJ8; MD Biosciences, St Paul, Minn), followed by streptavidin-allophycocyanin. In some experiments fluorescein isothiocyanate-conjugated anti-ST2 (DJ8, MD Biosciences) was used. 7-Aminoactinomycin D (BD Biosciences) or Fixable Viability Dye eFluor 506 (eBioscience) was added to exclude dead cells from analyses. In some experiments cells were fixed, permeabilized, and stained with biotin-conjugated anti-Foxp3 antibody (clone FJK-16s, eBioscience), followed by streptavidin-peridinin-chlorophyll-protein complex-Cy5.5 (BD Biosciences), phycoerythrin-conjugated anti-GATA3 antibody (clone L50-823, BD Biosciences), allophycocyanin-conjugated anti-IL-5 (clone TRFK5, BD Biosciences), and eFluor 660-conjugated anti-IL-13 (clone eBio13A, eBioscience). After washing, the cells were resuspended in PBS containing 1% BSA, fixed with 1% paraformaldehyde, and analyzed with the BD LSRII flow cytometer and FlowJo software (version 9.8; TreeStar, Ashland, Ore; BD Biosciences Immunocytometry Systems). The lymphocytic cell population was gated by using a forward-and side-scatter plot, and 7-aminoactinomycin D-positive or eFluor 506 1 dead cells were excluded from the analyses.
Sorting of lung Treg cells and culture
The entire population of CD4 Technologies) . Cells were stained as described above, and Treg cells were sorted with a FACSAria flow cytometer (BD Biosciences). Sorted lung Treg cells were cultured in round-bottom 96-well plates at 4 3 10 5 cells/mL and stimulated with 10 ng/mL PMA plus 500 ng/mL ionomycin in complete culture medium for 6 to 8 hours to examine cytokine protein production. Cell-free supernatants were harvested for quantitation of cytokine levels by using an ELISA. To examine St2 mRNA expression, sorted ST2 1 and ST2
2
Treg cells were then cultured with 40 ng/mL IL-33 under the stimulation of anti-CD3/anti-CD28 Dynabeads (Thermo Fisher Scientific, Life Technologies) for 24 hours. Cells were lysed for mRNA expression analyses, as described below. Alternatively, sorted lung Treg cells were cultured with 20 ng/mL IL-2 (R&D Systems, Minneapolis, Minn) with or without 40 ng/mL IL-33 for 96 hours. Cells were lysed immediately for mRNA analysis (see below) or stimulated with PMA plus ionomycin for 6 hours for analysis of cytokine proteins in cell-free supernatants.
Gene expression analyses
Cells were lysed in Trizol (Invitrogen), and total RNA was extracted and purified by using the PureLink RNA Mini Kit (Thermo Fisher Scientific), 
Airway tolerance model
Endotoxin-free OVA (<0.5 EU/mg, verified by using a Limulus amebocyte lysate assay; Wako Chemicals, Richmond, Va) was prepared with specific pathogen-free chicken eggs (Charles River Laboratories, Wilmington, Mass) under sterile conditions, as previously described. E2 Airway immunologic tolerance to OVA was induced by using a similar protocol, as previously described.
E3,E4 Briefly, endotoxin-free OVA (100 mg per dose) was intranasally administrated to naive BALB/c mice from day 212 to day 27. OVA (10 mg per dose, Sigma-Aldrich) plus alum was injected intraperitoneally on days 7 and 14 to verify the state of immunologic tolerance. Control mice received sterile PBS plus alum. Peripheral blood was collected on day 28 to examine plasma levels of IgE antibodies to OVA. On days 29, 30, and 31, mice were challenged intranasally with endotoxin-free OVA (100 mg per dose) and killed on day 32 with an overdose of pentobarbital. BAL fluid and lung tissue were collected for analyses. Mice were exposed to intranasal endotoxin-free OVA (100 mg per dose) alone, IL-33 alone (100 ng per dose, eBioscience), or OVA plus IL-33 on days 14 and 21 to examine the effects of airway administration of IL-33 on immune tolerance. In some experiments OVA alone, OVA plus IL-33, or OVA plus a mixture of allergen extracts (50 mg each of A alternata, A fumigatus, and HDM) was administered intranasally on days 0 and 7 without intraperitoneal administration of OVA plus alum.
Cell numbers in BAL fluid were counted with a hemocytometer, and differentials were determined in cytospin preparations stained with Wright-Giemsa. More than 200 cells were analyzed by using conventional morphologic criteria. The lungs were fixed with 10% formaldehyde and embedded in paraffin. Sections of fixed lung tissues were stained with hematoxylin and eosin and periodic acid-Schiff stain for histologic analysis.
Allergen-induced airway inflammation model
Mice were exposed to extracts of natural allergens to examine the effects of exposure to natural allergens, as described previously. E2 Briefly, extracts of natural allergens, including A alternata, A fumigatus, and HDM (Dermatophagoides pteronyssinus), were purchased from Greer Laboratories (Lenoir, NC). These extracts contained undetectable levels of endotoxin (<10 ng/mg extract and <0.50 ng per dose). Naive WT BALB/c mice, BALB/c-St2 2/2 mice, or BALB/c-Foxp3 EGFP reporter mice were exposed intranasally to a mixture of allergen extracts (10 mg each of A alternata, A fumigatus, and HDM plus 10 mg of endotoxin-free OVA in 50 mL of PBS) 3 times a week for up to 4 weeks after achievement of isoflurane inhalation anesthesia. Control mice received PBS alone. Mice were killed with an overdose of pentobarbital 12 hours after the last exposure (2-week model) or 24 hours after the last exposure (4-week model). Lungs were harvested, and single-cell suspensions were prepared and stained, as described previously.
ELISA for cytokine and antibody levels A, Experimental protocol. Naive BALB/c mice were treated intranasally with endotoxin-free OVA to establish tolerance. Mice were then exposed intranasally to OVA with a mixture of allergens (50 mg each of A alternata, A fumigatus, and HDM) or sensitized by means of intraperitoneal injection of OVA plus alum. Immune responses were examined by analyzing plasma levels of anti-OVA IgE on day 28 and then challenging mice with intranasal administration of OVA on days 29, 30, and 31. BAL fluid and lung tissue were collected 24 hours after the last challenge. B, Plasma levels of anti-OVA IgE are shown. C, Cell differential counts and cytokine levels in BAL fluid are shown. Data are shown as means 6 SEMs of 6 mice per group. *P < .05 and **P < .01 between the groups indicated by horizontal lines. Eos, Eosinophils; i.n., intranasal; i.p., intraperitoneal; Lym, lymphocytes; Mac, macrophages; Neu, neutrophils.
